The board of directors of CSPC Pharmaceutical Group Limited announced that SYH2045 developed by the Group has obtained approval granted by the National Medical Products Administration of the People's Republic of China to conduct clinical trials for the treatment of advanced malignant tumors in China. The Product, a Class 1 chemical drug with independent intellectual property rights, is a highly selective novel protein arginine methyltransferase 5 (PRMT5) inhibitor. Preclinical studies demonstrated that the Product is able to inhibit the methylation of arginine on histone and non-histone proteins to regulate gene transcription, mRNA splicing, expression, cell proliferation and differentiation, which in turn suppress the proliferation of tumor cells to exert anti-tumor effect.

The Product has high selectivity and strong inhibitory effect on PRMT5 with low off-target risk, excellent in vivo and in vitro activity and good safety profile, providing a promising clinical development value.